---
title: "Obefazimod (ABX464) in Ulcerative colitis: Definition and etiology"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Definition and etiology. Topics: Disease definition: chronic inflammation of the rectum and colon; Etiology: genetic predisposition, environmental exposures, barrier defects, microbiota, and immune dysregulation; Genetic susceptibility: shared loci with Crohn's disease, HLA associations, and low twin concordance; Environmental factors: Westernization, smoking cessation, and appendicitis. 4 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Disease definition: chronic inflammation of the rectum and colon

> “Ulcerative colitis is a lifelong inflammatory disease affecting the rectum and colon to a variable extent.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

> “Ulcerative colitis (UC) is a chronic inflammatory condition of the colon, with a prevalence exceeding 400 per 100 000 in North America.”

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

> “UC is characterized by chronic inflammation of the large intestine that is frequently associated with involvement of the rectum but often extends proximally to involve additional areas of the colon.”
> “Absence of rectal involvement has been noted in fewer than 5% of adult patients with UC at diagnosis but may be seen in up to a third of pediatric onset colitis (3).”
> “UC is an idiopathic chronic inflammatory condition of the rectum and colon which presents with variable degrees of clinical activity and severity and is associated with significant morbidity.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that affects the mucosa, the innermost lining of the intestinal wall in the large bowel (i.e., the colon and rectum).”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

<a id="topic-2.2.1.1-2"></a>

### Etiology: genetic predisposition, environmental exposures, barrier defects, microbiota, and immune dysregulation

> “Ulcerative colitis is thought to occur in people with a genetic predisposition following environmental exposures; gut epithelial barrier defects, the microbiota, and a dysregulated immune response are strongly implicated.”

Source: [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/)

> “Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown aetiology affecting the colon and rectum. Multiple factors, such as genetic background, environmental and luminal factors, and mucosal immune dysregulation, have been suggested to contribute to UC pathogenesis.”

Source: [Kobayashi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32913180/)

> “Despite advances in understanding environmental associations and risks, the causes of UC remain complex and unknown (2).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.1.1-3"></a>

### Genetic susceptibility: shared loci with Crohn's disease, HLA associations, and low twin concordance

> “Most genetic factors (67% of susceptibility loci) are shared between UC and Crohn’s disease (CD)”
> “Sixteen human leukocyte antigen (HLA) allelic associations (mostly class II) are described for UC”
> “Thirdly, despite the identification of many susceptibility loci, genetics explain only 19% of disease heritability in UC 18. The concordance rate amongst monozygotic twins for UC is only 6.3% (compared to nearly 60% in CD).”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

<a id="topic-2.2.1.1-4"></a>

### Environmental factors: Westernization, smoking cessation, and appendicitis

> “Westernisation is accompanied by new urban lifestyle, exposure to pollution, change in diet, access to antibiotics, better hygiene, and fewer infections, all considered as general contributory factors”
> “Appendicitis and smoking are protective in UC; smoking cessation can precede UC”

Source: [Porter et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7194476/)

> “Although the reasons for this increase remain incompletely understood, evidence suggests environmental factors associated with Westernization of society”
> “may have substantially contributed by altering mucosal immune responses to the intestinal microbiome in genetically susceptible individuals”

Source: [Hracs et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12158780/)

> “Potential precipitants of UC may include recent smoking cessation (20), non-steroidal anti-inflammatory drug (NSAID) use (21,22), as well as enteric infections (23).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
